Michael S. Gordon

27.9k total citations · 9 hit papers
325 papers, 15.3k citations indexed

About

Michael S. Gordon is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Michael S. Gordon has authored 325 papers receiving a total of 15.3k indexed citations (citations by other indexed papers that have themselves been cited), including 185 papers in Oncology, 112 papers in Molecular Biology and 90 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Michael S. Gordon's work include Cancer Immunotherapy and Biomarkers (73 papers), CAR-T cell therapy research (36 papers) and Renal cell carcinoma treatment (30 papers). Michael S. Gordon is often cited by papers focused on Cancer Immunotherapy and Biomarkers (73 papers), CAR-T cell therapy research (36 papers) and Renal cell carcinoma treatment (30 papers). Michael S. Gordon collaborates with scholars based in United States, United Kingdom and France. Michael S. Gordon's co-authors include David S. Mendelson, Kim Margolin, Jeffrey R. Infante, Michael B. Atkins, Ann A. Jakubowski, Jeffrey A. Sosman, Wilson H. Miller, Razelle Kurzrock, Janice Gabrilove and George W. Sledge and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Michael S. Gordon

318 papers receiving 14.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

1991 1.1k citations Wilson H. Miller, Michael S. Gordon et al. profile →
Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer

2001 744 citations Michael S. Gordon et al. Journal of Clinical Oncology profile →
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

2016 661 citations Michael S. Gordon, Sunil Sharma et al. Journal of Clinical Oncology profile →
Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma

2004 598 citations Michael S. Gordon et al. Journal of Clinical Oncology profile →
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

2018 567 citations Leisha A. Emens, Cristina Cruz et al. profile →
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 429 citations Jeffrey R. Infante, Michael S. Gordon et al. profile →
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

2012 424 citations Jeffrey R. Infante, Michael S. Gordon et al. profile →
Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

2016 409 citations Michael S. Gordon, John D. Powderly et al. Journal of Clinical Oncology profile →
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

2019 319 citations Matthew H. Taylor, Michael S. Gordon et al. profile →

Peers

Countries citing papers authored by Michael S. Gordon

Since Specialization

Citations

This map shows the geographic impact of Michael S. Gordon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Gordon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Gordon more than expected).

Fields of papers citing papers by Michael S. Gordon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael S. Gordon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Gordon. The network helps show where Michael S. Gordon may publish in the future.

Co-authorship network of co-authors of Michael S. Gordon

This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Gordon. A scholar is included among the top collaborators of Michael S. Gordon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Gordon. Michael S. Gordon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas 2025 ·Journal of Clinical Oncology ·Breelyn A. Wilky, Gary K. Schwartz, Michael S. Gordon, Anthony B. El-Khoueiry, Andrea J. Bullock, Brian S. Henick, Mark Agulnik, Arun S. Singh, Daruka Mahadevan, Justin Stebbing, Chloé Delépine, Dhan Chand, (unknown), (unknown), Benny Johnson, Joseph E. Grossman, Steven O’Day, Jonathan C. Trent, Robin L. Jones, Apostolia M. Tsimberidou	9
2	A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer 2025 ·ESMO Open ·Mohamed A. Gouda, Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam, Ulka N. Vaishampayan, Nizar M. Tannir, Jorge Chaves, Petros Nikolinakos, Alice C. Fan, Richard J. Lee, (unknown), Geoffrey I. Shapiro, Vijay Gandhi Linga, Shailender Bhatia, (unknown), Funda Meric‐Bernstam	17
3	Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration 2024 ·Molecular Carcinogenesis ·Alice N. Weaver, Wade T. Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S. Gordon, Kerry J. Rodabaugh, Neesha C. Dhani, Prakash Neupane, Matthew H. Taylor, (unknown), (unknown), Nathan R. Miselis, Scott Loughhead, Marshelle Warren, Howard Bernstein, Jens Peter Klußmann, Joaquina Baranda, Antonio Jimeno	2
4	756 First-in-human, open-label, multicenter, phase 1 clinical study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of anti Siglec-15 PYX-106 in subjects with advanced solid tumors 2023 ·SHILAP Revista de lepidopterología ·Alexander I. Spira, Michael S. Gordon, Jason T. Henry, Sandip Pravin Patel, Kartik Sehgal, Shiraj Sen, Randy F. Sweis, Marsha Crochiere, Shui He, (unknown), (unknown), Bin Zhang, Anthony W. Tolcher	1
5	Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors 2023 ·Journal for ImmunoTherapy of Cancer ·Anthony W. Tolcher, Michael S. Gordon, Kathleen M. Mahoney, (unknown), Marianna Zavodovskaya, Chia‐Hsiang Hsueh, Shuyan Zhai, Thomas Tarnowski, Juliane M. Jürgensmeier, Susanna Stinson, Ahmed A. Othman, (unknown), James Strauss	22
6	Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial 2022 ·Open Forum Infectious Diseases ·Kevin Winthrop, (unknown), (unknown), Scott Beegle, (unknown), Guenther Koehne, Ofra Barnett‐Griness, (unknown), (unknown), Patricia J. Anderson, (unknown), Gina Eagle, (unknown), Harold S. Minkowitz, Mark L. Levitt, Michael S. Gordon	10
7	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study 2021 ·Clinical Cancer Research ·Daniel P. Petrylak, Yohann Loriot, David R. Shaffer, Fadi Braiteh, John D. Powderly, Lauren C. Harshman, Paul Conkling, Jean‐Pierre Delord, Michael S. Gordon, Joseph W. Kim, Indrani Sarkar, Kobe Yuen, Edward E. Kadel, Sanjeev Mariathasan, Carol O’Hear, Sujata Narayanan, Marcella Fassò, Susheela Carroll, Thomas Powles	54
8	Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour 2021 ·European Journal of Cancer ·Suzanne George, Ping Chi, Michael C. Heinrich, Margaret von Mehren, Robin L. Jones, Kristen N. Ganjoo, Jonathan C. Trent, Hans Gelderblom, Albiruni Abdul Razak, Michael S. Gordon, Neeta Somaiah, (unknown), Julie Meade, Kelvin Shi, Ying Su, Rodrigo Ruiz‐Soto, Filip Jankú	22
9	Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma 2021 ·Nature Communications ·Antoni Ribas, Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon, Leonel F. Hernandez‐Aya, Donald P. Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy K. Mueller, Caroline Robert	1
10	Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio Ferreira González, Nathan Standifer, Jennifer Cann, Nicholas M. Durham, (unknown), Rakesh Kumar, Crystal S. Denlinger	40
11	A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma 2020 ·Clinical Cancer Research ·Monica Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold Keer, Aram Oganesian, Xiang Yao Su, Simone Jueliger, Anthony W. Tolcher	30
12	PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma 2020 ·Nature Communications ·Antoni Ribas, Alain P. Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael S. Gordon, Leonel F. Hernandez‐Aya, Donald P. Lawrence, Jose Lutzky, Wilson H. Miller, Katie M. Campbell, Bruno Delafont, Shannon Marshall, Nancy K. Mueller, Caroline Robert	60
13	Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders 2018 ·Clinical Cancer Research ·Rachel N. Grisham, Kathleen N. Moore, Michael S. Gordon, Wael A. Harb, (unknown), Darragh Halpenny, Vicky Makker, Carol Aghajanian	22
14	Abstract 2986: Atezolizumab in metastatic TNBC (mTNBC): Long-term clinical outcomes and biomarker analyses 2017 ·Cancer Research ·Peter Schmid, Cristina Cruz, Fadi S. Braiteh, Joseph P. Eder, Sara M. Tolaney, Irene Kuter, Rita Nanda, Cathie T. Chung, Philippe A. Cassier, Jean‐Pierre Delord, Michael S. Gordon, Yijin Li, Bo Liu, Carol O’Hear, Marcella Fassò, Luciana Molinero, Leisha A. Emens	92
15	Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC) 2017 ·Annals of Oncology ·Michael J. Morris, Nicholas J. Vogelzang, Oliver Sartor, Alison Armour, Michael D. Groaning, Richard A. Messmann, (unknown), Daniel P. Petrylak, Anthony W. Tolcher, Michael S. Gordon, Hani M. Babiker	5
16	Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Dalantercept, an Activin Receptor–like Kinase-1 Ligand Trap, in Patients with Advanced Cancer 2013 ·Clinical Cancer Research ·Johanna C. Bendell, Michael S. Gordon, Herbert I. Hurwitz, Suzanne F. Jones, David S. Mendelson, Gerard C. Blobe, Neeraj Agarwal, Carolyn H. Condon, Dawn Wilson, Amelia E. Pearsall, Yijun Yang, Ty McClure, Kenneth M. Attie, Matthew L. Sherman, Sunil Sharma	47
17	Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore	133
18	Effect of consumption of five portions of fruit and vegetables as juice shots on risk factors for cardiovascular disease 2006 ·Research Portal (King's College London) ·T. W. George, Elaine Paterson, (unknown), Michael S. Gordon, Julie A. Lovegrove	1
19	Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents 2006 ·Cancer and Metastasis Reviews ·Jocelyn Holash, Gavin Thurston, John S. Rudge, George D. Yancopoulos, Alex A. Adjei, Gabriele Bergers, Bronislaw Pytowski, Mark D. Pegram, Michael S. Gordon	16
20	Dramatic Response of Teratoma-Associated Non-Germ-Cell Cancer With All-Trans Retinoic Acid in a Patient with Nonseminomatous Germ Cell Tumor 2001 ·American Journal of Clinical Oncology ·Michael S. Gordon, Linda A. Battiato, David Finch, Robert J. Goulet, Lawrence H. Einhorn	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact